Celltrion acquires sales approval of antibody biosimilar ‘Truxima’ in Korea

Celltrion announced it acquired sales approval of its self-developed antibody biosimilar, CT-P10(brand name: Truxima, generic name: rituximab), from the Korea Ministry of Food and Drug Safety(MFDS) on the 16^th.

The MFDS approved Truxima to be used in indications, such as non-Hodgkin lymphomas, chronic lymphoblastic leukemia and rheumatoid arthritis; thus, it will be sold as a treatment for th...